Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cas...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1215 |
| _version_ | 1797407560075051008 |
|---|---|
| author | Juan Li Rui Song Zheng Yuan Zheng Xu Luodan Suo Qing Wang Yuan Li Yanlin Gao Xiaomei Li Xiaoyou Chen Jiang Wu |
| author_facet | Juan Li Rui Song Zheng Yuan Zheng Xu Luodan Suo Qing Wang Yuan Li Yanlin Gao Xiaomei Li Xiaoyou Chen Jiang Wu |
| author_sort | Juan Li |
| collection | DOAJ |
| description | This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources. |
| first_indexed | 2024-03-09T03:43:20Z |
| format | Article |
| id | doaj.art-488a684b4ee6464b9f2105f105b772fe |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:20Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-488a684b4ee6464b9f2105f105b772fe2023-12-03T14:36:42ZengMDPI AGVaccines2076-393X2022-07-01108121510.3390/vaccines10081215Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022Juan Li0Rui Song1Zheng Yuan2Zheng Xu3Luodan Suo4Qing Wang5Yuan Li6Yanlin Gao7Xiaomei Li8Xiaoyou Chen9Jiang Wu10Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaBeijing Ditan Hospital, Capital Medical University, Beijing 100013, ChinaBeijing Ditan Hospital, Capital Medical University, Beijing 100013, ChinaBeijing Municipal Health Commission, Beijing 100101, ChinaBeijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaXicheng Distract Center for Diseases Control and Prevention, Beijing 100120, ChinaBeijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaBeijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaBeijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaBeijing Ditan Hospital, Capital Medical University, Beijing 100013, ChinaBeijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing 100013, ChinaThis real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources.https://www.mdpi.com/2076-393X/10/8/1215COVID-19OmicronDeltapneumoniainactive vaccineeffect |
| spellingShingle | Juan Li Rui Song Zheng Yuan Zheng Xu Luodan Suo Qing Wang Yuan Li Yanlin Gao Xiaomei Li Xiaoyou Chen Jiang Wu Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 Vaccines COVID-19 Omicron Delta pneumonia inactive vaccine effect |
| title | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
| title_full | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
| title_fullStr | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
| title_full_unstemmed | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
| title_short | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
| title_sort | protective effect of inactivated covid 19 vaccines against progression of sars cov 2 omicron and delta variant infections to pneumonia in beijing china in 2022 |
| topic | COVID-19 Omicron Delta pneumonia inactive vaccine effect |
| url | https://www.mdpi.com/2076-393X/10/8/1215 |
| work_keys_str_mv | AT juanli protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT ruisong protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT zhengyuan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT zhengxu protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT luodansuo protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT qingwang protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT yuanli protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT yanlingao protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT xiaomeili protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT xiaoyouchen protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT jiangwu protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 |